Heart Failure – Landscape & Forecast – Disease Landscape & Forecast

Acute and chronic heart failure (HF) have distinct treatment pathways, and both are covered in this report. Although much progress has been made in the pharmacological management of HF, this progress relates mainly to chronic HF (CHF), particularly HF with reduced ejection fraction (HFrEF). Substantial unmet need remains in the treatment of HF with preserved ejection fraction (HFpEF). This report provides insight into the current and future CHF and acute HF (AHF) markets, as well as the expected dynamics of the HFrEF and HFpEF markets following the market entries of several new therapies (Boehringer Ingelheim / Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, and Bayer / MSD’s vericiguat). This report also assesses how the AHF market will evolve given the lack of new drug launches for this patient population


  • How large are the treatable AHF, HFrEF, and HFpEF populations, and how will diagnosis rates change over time?
  • What is the state of treatment for heart failure? What are the most important drugs and why? Which clinical needs remain unfulfilled?
  • How will the use of Entresto evolve over the forecast period?
  • How will the treatment of HFpEF change following the launches of the first evidence-based drugs for this population?
  • For which emerging therapies do thought leaders express the most enthusiasm, and what level of market penetration can they expect?


United States, EU5, Japan.


20 country-specific interviews with thought-leading cardiologists; supported by survey data collected for this and other Clarivate research.


Diagnosed events of AHF by country and diagnosed prevalence of CHF by country, segmented by ejection fraction.


10-year, annualized, drug-level sales and patient shares of key HF therapies through 2032, segmented by brands / generics and ejection fraction (HFrEF and HFpEF).


Phase 3/PR: 4 drugs; Phase 2: 8 drugs.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports